Corbus Pharmaceuticals Announces FDA Clearance To Initiate Tempo-1 Registrational Study Of Crb-701 In Patients With 2L Oropharyngeal Cancer
CRBP•FDA clears Tempo-1 registrational study
July 28 (Reuters) - Corbus Pharmaceuticals Holdings Inc. CRBP.O:
- Corbus Pharmaceuticals announces FDA clearance to initiate Tempo-1 registrational study of CRB-701 in patients with 2L oropharyngeal cancer.
- Corbus Pharmaceuticals announces FDA clearance to initiate Tempo-1 registrational study of CRB-701 in patients with 2L oropharyngeal cancer.
- Corbus Pharmaceuticals Holdings Inc. expects to initiate enrollment in Tempo-1 in September 2026.
Source text: ID:nGNX2bK0s
Further company coverage: CRBP.O
